Combined Treatment of Murine Fibrosarcoma with Chemotherapy (Paclitaxel), Radiotherapy, and Intratumoral Injection of Dendritic Cells.
- Author:
Ji Won BYUN
1
;
Hyeon Sook LEE
;
Sun Uk SONG
;
Si Won LEE
;
Soon Ki KIM
;
Woo Chul KIM
;
Moon Hee LEE
;
Gwang Seong CHOI
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Combined modality therapy; Dendritic cells; Fibrosarcoma; Paclitaxel; Radiotherapy
- MeSH: Animals; Combined Modality Therapy; Dendritic Cells*; Drug Therapy*; Fibrosarcoma*; Lymphocytes; Memory; Mice; Paclitaxel; Radiotherapy*; T-Lymphocytes, Cytotoxic
- From:Annals of Dermatology 2014;26(1):53-60
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: New antitumor therapeutic strategies aim to combine different approaches that are able to induce tumor-specific effector and memory T cell responses that might control tumor growth. Dendritic cells (DCs) have the capacity to induce antigen-specific cytotoxic T lymphocytes. We have previously shown that the combined treatment of paclitaxel chemotherapy (Chemo) and injection of DCs led to complete tumor regression. OBJECTIVE: The goal of this study was to evaluate synergistic antitumor effect of a triple combination treatment comprising radiotherapy, paclitaxel Chemo and intratumoral injection of syngeneic bone marrow-derived DCs on murine fibrosarcoma, compared to other single or double combination treatments. METHODS: For the murine fibrosarcoma model, naive C57BL/6 mice were inoculated intradermally with 2x10(3) MCA102 cells in the right upper flank. Mice were assigned to five groups (untreatedcontrol, RT alone, RT+Chemo, RT+DC, and RT+Chemo+DC), with eight mice in each group. In vitro cytotoxicity assays were performed to assess the immune activity. The persistence of tumor-specific immunity was determined by second tumor challenge in mice with complete tumor regression. RESULTS: The triple combination treatment showed a significantly enhanced therapeutic efficacy by decreasing tumor size and inducing complete tumor regression, resulting in a cure of 50% of mice. The results of in vitro cytotoxicity assays and the second tumor challenge experiment strongly indicated the induction of a tumor-specific cytotoxic T lymphocyte response and acquisition of prolonged tumor immunity. CONCLUSION: These findings suggest that the triple combination treatment can be a promising strategy for the treatment of murine fibrosarcoma.
